MELBOURNE, Australia and SAN FRANCISCO, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the…
CEO of family company Angelini Industries will also lead the pharmaceutical company from today, bringing strong leadership experience and strategic…
HOUSTON, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Hopstem Biotechnology Inc. (hereinafter referred to as "Hopstem"), a company dedicated to the…
EMERYVILLE, Calif., Jan. 20, 2026 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (Nasdaq: BIOA) (“BioAge”, “the Company”), a clinical-stage biopharmaceutical company…
Immersive AI Education & Experience for Home Care and Senior Living Leaders Not Yet Using SensiPALO ALTO, Calif., Jan. 20,…
Immersive AI Education & Experience for Home Care and Senior Living Leaders Not Yet Using SensiPALO ALTO, Calif., Jan. 20,…
Immersive AI Education & Experience for Home Care and Senior Living Leaders Not Yet Using SensiPALO ALTO, Calif., Jan. 20,…
The DROP-FPF trial is the first Phase 3 trial in interstitial lung disease (ILD) to use automated, quantitative high-resolution CT scan…
The DROP-FPF trial is the first Phase 3 trial in interstitial lung disease (ILD) to use automated, quantitative high-resolution CT scan…
The DROP-FPF trial is the first Phase 3 trial in interstitial lung disease (ILD) to use automated, quantitative high-resolution CT scan…